Business / Finance

RSS

PTC restructures collaboration with Genzyme

PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries.

2 Sep 2011

UnitedHealthcare to administer major Calif. physicians groups

UnitedHealth Group continues to expand its Optum health services division, entering into an agreement to handle non-clinical operations at one of California's largest physicians groups.

2 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

SuperGen is now Astex Pharmaceuticals

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011.

2 Sep 2011

FTC presses for more competition on generic drugs

Some drug makers are using an indirect method to delay competition from low-cost generic products by promising not to introduce their own generic versions if a potential competitor delays its entry into the market, the Federal Trade Commission said in a report on Wednesday.

2 Sep 2011

Eclipse extends tender offer to acquire Icagen for $6.00 per share

Pfizer Inc. and Icagen, Inc. announced today that Pfizer's wholly-owned subsidiary, Eclipse Acquisition Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.

2 Sep 2011

Medtronic acquires PEAK and Salient

Medtronic, Inc. today announced that it has completed the acquisition of two privately-held companies, PEAK Surgical, Inc. and Salient Surgical Technologies, Inc. Both of the companies are focused on advanced energy surgical technologies and will broaden Medtronic Surgical Technologies' portfolio of innovative surgical products to meet customer and patient needs worldwide.

From Medtronic 2 Sep 2011

Study reveals how pharmaceutical managers can maximize the return on marketing investments

Research in Marketing Science by Professor Kamel Jedidi, John A. Howard Professor of Business, Marketing, Columbia Business School; Professor Oded Netzer, Philip H. Geier Jr. Associate Professor, Marketing, Columbia Business School; and Professor Ricardo Montoya, Department of Industrial Engineering, University of Chile, Santiago, Chile, reveals how pharmaceutical managers can maximize the return on marketing investments - by determining the physicians to target as well as when and how to target them.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Insight Pharmaceuticals announces acquisition of MONISTAT business from McNEIL-PPC

Insight Pharmaceuticals, a portfolio company of Swander Pace Capital, announced today that it has acquired the MONISTAT North American brand portfolio from McNEIL-PPC, Inc.

31 Aug 2011

Valeant to acquire Afexa for C$76 million in cash

Valeant Pharmaceuticals International, Inc., announced today that it has agreed to acquire Afexa Life Sciences Inc. for approximately C$76 million.

31 Aug 2011

Omega board authorizes repurchase of $100M shares of common stock

Omega Healthcare Investors, Inc., announced today that its Board of Directors has authorized the repurchase of up to $100 million of its outstanding common stock, from time to time over the next 12 months.

31 Aug 2011

Stereotaxis reaffirms commercialization plans for Epoch, Odyssey platforms into standard labs

The Board of Directors of Stereotaxis, Inc. announced today following its regularly scheduled board meeting that it reaffirmed the Company's plans for both the launch of the Epoch platform and expansion of the Odyssey platform into standard labs.

30 Aug 2011

EMD Millipore announces acquisition of Amnis

EMD Millipore, the Life Science division of Merck KGaA of Germany, today announced it has agreed to acquire Seattle-based Amnis Corporation. Amnis designs, manufactures and markets high speed cell imaging instrumentation.

30 Aug 2011

Avantra is now Courtagen Life Sciences

Avantra Biosciences Corporation today announced that effective immediately it is changing its name to Courtagen Life Sciences, Inc. The company will continue to use the Avantra name for their proteomics portfolio, which includes the Avantra Biomarker System.

30 Aug 2011

EMD Millipore acquires Amnis

Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced that the company has been acquired by EMD Millipore, the Life Science division of Merck KGaA of Germany.

30 Aug 2011

RaySearch Laboratories reports net sales of SEK 47.6 M for January 1 - June 30, 2011

RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.

30 Aug 2011

UHC Supply Chain helps University of Iowa Hospitals and Clinics to save $14M in 18 months

A supply chain strategy built on excellence in customer service and a partnership with UHC Supply Chain has helped UHC member University of Iowa Hospitals and Clinics initiate 35 projects that saved more than $14 million in 18 months.

30 Aug 2011

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

BioAmber selects Sarnia as location for first North American biosuccinic acid plant

BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.

29 Aug 2011